News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
224 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37191)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53928)
2023 (42568)
2024 (38486)
2025 (17535)
Month
January (2946)
February (2976)
March (2714)
April (2913)
May (3639)
June (2347)
Day
1 (247)
2 (153)
3 (119)
4 (61)
7 (125)
8 (120)
9 (108)
10 (98)
11 (60)
13 (8)
14 (122)
15 (104)
16 (130)
17 (119)
18 (31)
21 (89)
22 (113)
23 (192)
24 (172)
25 (121)
28 (196)
29 (201)
30 (224)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
Day
1
2
3
4
7
8
9
10
11
13
14
15
16
17
18
21
22
23
24
25
28
29
30
Cancer
AACR 2025 Tracker: Merck, GSK, Roche and More Present Key Data
The American Association for Cancer Research’s annual conference featured updates from several companies on key candidates and assets, including Merck’s Keytruda and GSK’s Jemperli.
April 30, 2025
·
8 min read
·
BioSpace Editorial Staff
Tariffs
China Still Go-To Source for New Drugs Despite Tariff Minefield
Policy uncertainties are impacting biopharma dealmaking from continent to continent, with companies being asked to walk a tightrope on their relations with China.
April 30, 2025
·
10 min read
·
Annalee Armstrong
C-suite
Top CEO-to-Employee Pay Gaps in 2024
What a CEO makes can be staggering from the seat of a rank-and-file employee, whose pay is typically in the five-to-six digit range.
April 30, 2025
·
1 min read
·
Annalee Armstrong
Leadership
Leadership Lab: 9 Tips for Fully Benefiting From an Executive Coach
Learn how to extract the full value from executive coaching, starting with being open and honest with your coach.
April 30, 2025
·
4 min read
·
Michael Pietrack
Mergers & acquisitions
Novartis Drops up to $1.7B to Bolster Oligo Pipeline With Regulus Buy
At the heart of the acquisition is Regulus’ farabursen, an miRNA-targeting oligonucleotide in early-stage development for rare autosomal dominant polycystic kidney disease.
April 30, 2025
·
2 min read
·
Tristan Manalac
Deals
Novartis Strikes on M&A, Leading a Line of Big Pharmas With Cash to Spend
Many companies have foreshadowed deals to come during earnings calls in recent days. The return of M&A would be a welcome sign for the biopharma ecosystem, which has been battered by macro headwinds such as tariffs and the possibility of new drug pricing pressures.
April 30, 2025
·
5 min read
·
Annalee Armstrong
Prostate cancer
AstraZeneca’s Truqap Posts Another Pivotal Disappointment as Phase III Prostate Cancer Study Fails
The drug, a small molecule protein inhibitor, brought in $132 million in the first quarter, missing consensus estimates by 17%.
April 30, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Major Shareholder Opposes Acelyrin’s Merger With Alumis, Prefers Wind-Down
It’s been a fraught road for the proposed merger between Acelyrin and Alumis, with Tang Capital’s Concentra Biosciences in February threatening to upend the deal with a proposed $3-per-share acquisition of Acelyrin.
April 30, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Entrada Cuts 20% of Workforce, Targeting Research Employees
Entrada is paring back its research staff even as it gears up to hire employees to support a planned clinical trial for a Duchenne muscular dystrophy candidate.
April 30, 2025
·
1 min read
·
Angela Gabriel
Earnings
GSK Optimistic About M&A Prospects Despite Trump Tariff Threats
GSK’s dealmaking will be “cautious and disciplined” under the current trade war, but the pharma will focus on looking for “opportunities created” amid these tensions, according to CEO Emma Walmsley. The company also reported a 4% earnings bump for the quarter.
April 30, 2025
·
2 min read
·
Tristan Manalac
1 of 23
Next